Legal Representation
Attorney
Monica Riva Talley
USPTO Deadlines
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 29, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Sep 29, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Sep 9, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Sep 8, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Sep 8, 2025 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jul 4, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 3, 2025 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Jul 1, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Mar 5, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 4, 2025 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Aug 30, 2024 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Aug 30, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Aug 30, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 30, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 7, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 6, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 6, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Mar 6, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Sep 8, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 6, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Sep 6, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Sep 6, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 8, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 6, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 6, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 6, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 6, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jul 12, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 12, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 22, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 9, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 1, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 9, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 8, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 8, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 8, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 8, 2021 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 8, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 7, 2021 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | Loading... |
| Jan 21, 2021 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Jan 21, 2021 | GNSL | F | LETTER OF SUSPENSION E-MAILED | Loading... |
| Jan 21, 2021 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Jan 14, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 14, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 11, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment and prophylaxis of infectious diseases, immune system diseases and disorders, auto immune system diseases, and blood disorders, none of the foregoing related to oncology
First Use Anywhere:
20240800
First Use in Commerce:
20240800
Additional Information
Pseudo Mark
APT EVO RESEARCH AND DEVELOPMENT
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"RESEARCH AND DEVELOPMENT"